abstract |
Providing new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl) -2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl) amino)ethylidene)amino)oxy)-cyclopropanecarboxylic acid (referred to herein as compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy. |